BD Cato Alternative for TPN: MyTotalMix for Hospital Pharmacy
MyTotalMix is a parenteral nutrition (TPN) system developed for 15 years exclusively in this domain - not an oncology platform adapted for TPN, but a tool designed from the ground up around 2-in-1/3-in-1 admixtures: with built-in ESPGHAN dose validation, two dosing paths (adults and older children, and neonates and younger children with tighter limits), a Polish-language interface, and logic built around the realities of Polish hospital pharmacy. It runs standalone, with no requirement to integrate with the hospital system, and the current version is a fresh code rewrite on a modern stack. BD Cato represents a different category: it's IV medication workflow software for hospital pharmacy, developed since 1999 (according to the vendor, in use at more than 400 sites across Europe, North America, and the Middle East, as of April 2020), also offered in Poland. Its core is the preparation of cytotoxic drugs and other critical substances (the Prescribe, Pharmacy, and ReadyMed modules) - parenteral nutrition is handled there by a separate module, BD Cato for TPN, added on top of a broader platform. Both systems are standalone software not tied to one hardware line, so this comparison isn't 'vendor-neutral vs. device-bundled'; it comes down to specialization: a general IV platform with a TPN module versus a system built for 15 years exclusively around parenteral nutrition.
Last updated: July 2, 2026
BD Cato vs. MyTotalMix: similar architecture, different specialization
Architecturally, the two systems sit on the same side of the market. BD Cato treats compounding robots as an optional part of its ecosystem and states integrations with devices from multiple manufacturers (including Loccioni Apoteca, Fresenius PharmaHelper, Grifols Kiro, and ARxIUM RIVA), while integration with prescribing and EMR systems is possible but not required - the system can run standalone. MyTotalMix works the same way: it plugs into the compounders and label printers the pharmacy already operates, and HIS integration over API is an option arranged individually. The difference lies in the product's center of gravity. BD Cato grew out of cytotoxic drug preparation and remains, first and foremost, a general IV workflow platform in which TPN is one module. MyTotalMix has been developed for 15 years exclusively in the parenteral nutrition domain - the entire system, from the physician's order to the 2-in-1/3-in-1 admixture formula sent to the compounder, is designed around TPN.
Dose validation: generic limits vs. explicit ESPGHAN guidelines
The BD Cato for TPN module states real clinical validation: automatic dosage calculations, blocking the save when maximum values are exceeded (e.g. total volume or per-ingredient dose limits), and monitoring of maximum glucose concentration with automatic dilution recalculation. However, the vendor's materials don't indicate which clinical guidelines those limits are based on - neither ESPGHAN nor any other named standard appears in the publicly available descriptions, and neither does the topic of pediatric or neonatal populations. In MyTotalMix, ESPGHAN guidelines are the explicitly stated foundation of validation: limits configured per organization, with two dosing paths - adults and older children, and, with tighter limits, neonates and younger children - and pharmacist verification as a step in the process.
The Polish market and 15 years of TPN domain focus
BD Cato is offered in Poland - the vendor maintains a Polish-language product page, and the system is known in domestic cytostatic preparation units. MyTotalMix was created and is developed in Poland, in direct collaboration with domestic hospital pharmacies, around the realities of the Polish hospital: the physician's nutrition ordering process, pharmacist verification, and production in the parenteral nutrition unit. On top of that come 15 years of domain experience in TPN, with the current version of the application being a full code rewrite on a modern technology stack - mature nutrition logic without the technical debt of older platforms.
MyTotalMix vs. BD Cato - compared across eight dimensions
This comparison relies solely on BD's publicly available materials about BD Cato and the BD Cato for TPN module. Where the vendor's materials don't provide detail, that is explicitly noted.
| Dimension | MyTotalMix | BD Cato |
|---|---|---|
| Product specialization | A system dedicated exclusively to parenteral nutrition (TPN) | General IV workflow platform (cytotoxic drugs and other critical substances); TPN handled by the separate BD Cato for TPN module |
| ESPGHAN dose validation | ESPGHAN dose limits configurable per organization, with pharmacist verification | TPN module states maximum-value checks (volume, ingredient doses, glucose concentration); vendor materials don't reference ESPGHAN or other named guidelines |
| Age-based dosing pathways | Two dosing paths: adults and older children, and neonates and younger children, with tighter limits for the latter group | Vendor materials don't describe pediatric or neonatal pathways in the TPN module |
| Hardware dependency | Device-agnostic, plugs into the compounders you already own | Also device-agnostic: stated integrations with robots from multiple manufacturers (incl. Loccioni Apoteca, Fresenius PharmaHelper, Grifols Kiro, ARxIUM RIVA); TPN module with interfaces to TPN compounders |
| HIS integration | Optional: orders are entered directly in the system, with API integration arranged individually with each hospital | Optional: vendor states standalone operation as well as integrations with prescribing and EMR systems (HL7) |
| Audit trail & versioning | Full change audit trail, prescription and order versioning | Vendor states a complete audit trail for compounding procedures; prescription/order versioning not described publicly |
| Access control | RBAC with pharmacist, technician, and admin roles | Functional role split in the workflow described (physician, pharmacist, technician, nurse); RBAC detail not described publicly |
| Product maturity | 15 years of domain development in TPN, current version is a full rewrite on a modern stack | On the market since 1999; more than 400 sites across Europe, North America, and the Middle East per vendor (as of April 2020) |
When BD Cato may be the better choice
If a unit is looking for one platform for its entire IV medication operation - with a focus on cytotoxic drugs, gravimetric preparation control, and integrations with compounding robots from multiple manufacturers - that's BD Cato's profile, where parenteral nutrition is one of several areas it handles. If instead the need is a system specialized in TPN - explicit ESPGHAN dose validation with two dosing paths, prescription and order versioning, RBAC with pharmacist, technician, and admin roles, and a system developed in Poland around the realities of Polish hospital pharmacy - that's exactly MyTotalMix's category, without deploying a broad IV platform if the pharmacy doesn't need one.
Common questions about MyTotalMix as a BD Cato alternative
- How is MyTotalMix different from BD Cato?
- Both systems are standalone software not tied to one hardware line, but their focus differs. BD Cato is a general workflow platform for IV medication preparation (cytotoxic drugs above all), with parenteral nutrition handled by the separate BD Cato for TPN module. MyTotalMix is built entirely around TPN: from the physician's order, through ESPGHAN dose validation and pharmacist verification, to the 2-in-1/3-in-1 admixture formula for the compounder.
- Are BD Cato and MyTotalMix both independent of the compounder manufacturer?
- Yes, both. BD states integrations with compounding robots from multiple manufacturers (including Loccioni Apoteca, Fresenius PharmaHelper, Grifols Kiro, and ARxIUM RIVA), and the TPN module offers interfaces to TPN compounders. MyTotalMix plugs into the compounders and label printers the pharmacy already operates, over barcode and OAuth. On the hardware layer the two systems take a similar approach, but that doesn't change the difference in specialization: MyTotalMix remains a system built exclusively around TPN, not a module of a general IV platform.
- Does BD Cato validate TPN doses against ESPGHAN guidelines?
- BD's materials about the BD Cato for TPN module describe automatic dosage calculations, blocking the save when maximum values are exceeded, and glucose concentration monitoring, but they don't reference ESPGHAN or any other named clinical guidelines, nor pediatric/neonatal pathways. In MyTotalMix, ESPGHAN guidelines are the explicitly stated basis of validation, with limits configured per organization and two dosing paths: adults and older children, and, with tighter limits, neonates and younger children.
- Does MyTotalMix support parenteral nutrition for neonates?
- Yes. MyTotalMix runs a separate dosing path for neonates and younger children, with tighter limits than the path for adults and older children, plus ESPGHAN dose limits configurable per organization and pharmacist verification as a step in the process.
- Does deploying MyTotalMix require a HIS integration?
- No. MyTotalMix runs standalone, and nutrition orders are entered directly in the system. HIS integration is possible over API and arranged individually with each hospital - it's an option, not a deployment requirement. BD also states that BD Cato can operate standalone, but for a pharmacy that only needs TPN, MyTotalMix's simpler deployment comes from not having to stand up an entire IV platform to use one module of it.
- How much does MyTotalMix cost compared to BD Cato?
- MyTotalMix pricing is individual and depends on the pharmacy size and deployment scope. Because MyTotalMix is a TPN-dedicated system, the pharmacy doesn't pay for a broad IV workflow platform if all it needs is parenteral nutrition support. Book a demo to get a quote tailored to your pharmacy.
See MyTotalMix as a BD Cato alternative for TPN
Book a short demo and watch ESPGHAN dose validation, neonate-to-adult dosing pathways, and the fit with your existing hardware, live.